{"name":"Ingrid Pabinger, MD","slug":"ingrid-pabinger-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"corticosteroids (Aprednislon)","genericName":"corticosteroids (Aprednislon)","slug":"corticosteroids-aprednislon","indication":"Inflammatory and autoimmune conditions (specific approved indications not clearly documented in available sources)","status":"marketed"}]}],"pipeline":[{"name":"corticosteroids (Aprednislon)","genericName":"corticosteroids (Aprednislon)","slug":"corticosteroids-aprednislon","phase":"marketed","mechanism":"Aprednislon is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Inflammatory and autoimmune conditions (specific approved indications not clearly documented in available sources)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE9Qcm4zX2Joc1RMLVRvUDhsNXhXeVN3VlQ5S2ZTa0NnZzVZdjRWZGt2Z2R1c0NmVW9fWTRsWXRMZkNuMk5vSGdLY2FkZDdTb2k4RGFoS3JaQnY2ZklIYXg5c0dzT3Y5LU1lUVdZ?oc=5","date":"2022-07-26","type":"trial","source":"Wiley Online Library","summary":"Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Wiley Online Library","headline":"Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from p","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9XbEtDU1RlYnVFbFlidnVjd0U0NEJWcmJJdjVTdmpFal9VZ0MyU0xuRDYzT1NqMFk5VVlXQkJqb0VVcFJ1RDBqanQzM2ZVZFNjemZTTHh2V1FUR2NnZERr?oc=5","date":"2010-11-11","type":"pipeline","source":"NEJM","summary":"Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia - NEJM","headline":"Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE83MTljR29MOEJTT25DTWtSOGlldkpvaFg5Y0ZWSU1yOTJUc1FHcWNNT29GZnB0Y1dBb0lKclFXSWlhTlBzdHlrOTZCOFlGNmFScWgtUURuTDQxb1RYSnh1UQ?oc=5","date":"2010-11-11","type":"pipeline","source":"NEJM","summary":"Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia - NEJM","headline":"Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}